Table 6.
Tripodi† | Beck* | Romero* | McKenna‡ | Lazarovitch* | Corredoiran | Sheng* | Corredoira | Ben-Chetrit* | Total | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2004 | 2008 | 2011 | 2011 | 2013 | 2013b | 2014 | 2017 | 2017 | |||||||||||||
Identification | technique | phenotypic | 16s rRNA | MALDI-TOF, 16s rRNA, sodA | n.d. | VITEK 2, groES/groEL | phenotypic, VITEK2 | VITEK 2, 16s rRNA, sodA, groES/groEL | API20 Strep, VITEK 2, 16s rRNA, sodA | MALDI-TOF | |||||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
SGG cases | 28 | 21 | 14 | 6 | 99 | 31 | 257 | 6 | 462 | ||||||||||||
adenomas | 13 | 46.4 | 5 | 23.8 | 3 | 21.4 | – | – | – | – | 52 | 52.5 | 5 | 16.1 | 103 | 40.1 | 1 | 16.7 | 182 | 39.4 | |
carcinomas | 1 | 3.6 | 2 | 9.5 | 1 | 7.1 | – | – | – | – | 18 | 18.2 | 5 | 16.1 | 25 | 9.7 | 2 | 33.3 | 54 | 11.7 | |
neoplasia | 14 | 50.0 | 7 | 33.3 | 4 | 28.6 | – | – | 3 | 50.0 | 70 | 70.7 | 10 | 32.3 | 128 | 49.8 | 3 | 50.0 | 239 | 51.7 | |
SGP cases | 11 | 24 | 13 | 126 | 26 | 200 | |||||||||||||||
adenomas | – | – | 0 | 0.0 | 11 | 45.8 | – | – | – | – | – | – | 8 | 6.3 | – | – | 3 | 11.5 | 22 | 11.0 | |
carcinomas | – | – | 0 | 0.0 | 0 | 0.0 | – | – | – | – | – | – | 19 | 15.1 | – | – | 4 | 15.4 | 23 | 11.5 | |
neoplasia | – | – | 0 | 0.0 | 11 | 45.8 | – | – | 4 | 30.8 | – | – | 27 | 21.4 | – | – | 7 | 26.9 | 49 | 24.5 | |
SL cases | 14 | 5 | 4 | 4 | 6 | 33 | |||||||||||||||
adenomas | – | – | 3 | 21.4 | 0 | 0.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | 2 | 33.3 | 5 | 15.2 | |
carcinomas | – | – | 1 | 7.1 | 0 | 0.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | 0 | 0.0 | 1 | 3.0 | |
neoplasia | – | – | 4 | 28.6 | 0 | 0.0 | – | – | 2 | 50.0 | – | – | 0 | 0.0 | – | – | 2 | 33.3 | 8 | 24.2 | |
SII cases | 2 | 1 | 11 | 14 | |||||||||||||||||
adenomas | – | – | – | – | 1 | 50.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | – | – | 1 | 7.1 | |
carcinomas | – | – | – | – | 0 | 0.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | – | – | 0 | 0.0 | |
neoplasia | – | – | – | – | 1 | 50.0 | – | – | 1 | 100.0 | – | – | 0 | 0.0 | – | – | – | – | 2 | 14.3 | |
SGM cases | 2 | 2 | |||||||||||||||||||
adenomas | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2 | 100.0 | 2 | 100.0 | |
carcinomas | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 0.0 | 0 | 0.0 | |
neoplasia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2 | 100.0 | 2 | 100.0 | |
All SBSEC | |||||||||||||||||||||
cases | 30 | 46 | 45 | 37 | 24 | 135 | 172 | 257 | 40 | 786 | |||||||||||
adenomas | 13 | 43.3 | 8 | 17.4 | 15 | 33.3 | 9 | 24.3 | 0 | 0.0 | 58 | 43.0 | 13 | 7.6 | 103 | 40.1 | 8 | 20.0 | 227 | 28.9 | |
carcinomas | 1 | 3.3 | 3 | 6.5 | 1 | 2.2 | 3 | 8.1 | 0 | 0.0 | 20 | 14.8 | 24 | 14.0 | 25 | 9.7 | 6 | 15.0 | 83 | 10.6 | |
neoplasia | 14 | 46.7 | 11 | 23.9 | 16 | 35.6 | 12 | 32.4 | 10 | 41.7 | 78 | 57.8 | 37 | 21.5 | 128 | 49.8 | 14 | 35.0 | 320 | 40.7 |
All cases associated with neoplasia were S. bovis biotype I (listed under SGG), 2 SB cases had SB biotype II. Bold numbers represent total number of SBSEC cases per study (in columns) or total number of SBSEC cases per subspecies (in lines).
Studies with identification of SB subspecies.
21 of 37 did not undergo colonoscopy, of 14 that underwent colonoscopy at index 7 had adenomas and 3 a carcinoma.
n Devided into SB biotype I and II, biotype I is listed under SGG, 36 SB biotype II cases in total.
Untyped SBSEC cases are only included under “all SBSEC cases” and the total SBSEC species might thus not be equal to the sum of individual species cases.